Elmar Nurmemmedov

Oral PDE10 inhibitor ADT-030 curbed KRAS-mutant pancreatic cancer growth and metastasis in mouse models, stayed active in KRAS-inhibitor-resistant cells, and shifted tumor immune profiles.

This study shows that inhibiting CHD4, a component of the NuRD complex, reduces Treg cells and enhances antitumor immunity without causing autoimmunity.

This study develops and characterizes abbapolins, non-peptidic PLK1 PBD inhibitors, showing in vivo efficacy against prostate cancer and synergy with enzalutamide.

The paper introduces a fluorescence-based method to quantify drug-target engagement in temperature series using split-RNase S complementation.

This study identifies a novel peptide, JM2, that disrupts Cx43-microtubule interaction in GBM stem-like cells, reducing their survival and tumorigenicity.